Professional Experience
Partner, Risk Management Resources LLC (2004 - Present)

• Principal role in database development, technical/analytic plan writing, data analysis, and graphical creations
• Databases warehoused and analyzed: General Practice Research Database (GPRD), The Health Improvement Network database (THIN), Pharmetrics, clinical databases

Principal, Analytic Consulting Solutions, Inc. (2000 - Present)

• Principal role in all database development, statistical analyses, and graphical creations
• Works in team effort with client scientists to show/describe analytic details and develop analytic plans
• Designs detailed analytic plans with collaborating client to outline project deadlines and manage analytic tasks
• Databases developed, investigated, and analyzed: GPRD, THIN, clinical trial data, large insurance claims databases (Pharmetrics, UHC/Ingenix, BCBS), physician practice databases, NHANES, Medicaid, FDA adverse event reporting system data, pharmacy transaction data, case report form data
• Areas of research: respiratory, arthritis, HIV, antibiotics, diabetes, allergic rhinitis, cancer
• Conducted epidemiologic/safety analyses of a multi-center trial database and prepared graphics/slides for FDA Advisory Committee meeting for the approval of a new respiratory drug
• Designs episodes of therapy to derive epidemiologic differences in utilization, cost of care, and discontinuation / switching patterns
• Perform survival analysis and logistic/poisson regression to compare treatment groups by multiple outcomes
• Clients: Amgen, Blue Cross Blue Shield Association, Boehringer-Ingelheim Pharmaceuticals, EPIC, Glaxo-SmithKline, i3 (Ingenix), Joel Hay Consulting, Merck & Co. Inc., Pharmacia Corporation, University of Southern California, University of Washington

Senior Director R&D, Quintiles Transnational – Bioinformatics division (1998 –2001)

• · Developed models and processes for the Rx Market Monitor®, Rx Dosage Insight®, Pharmacy Cost Analyzer®, and MDprofiler® (OLAP) tool which queries in-house real-time pharmacy transaction data used for pharmaceutical market-research analyses
• · Managed analytic team conducting custom studies using the nation’s largest real-time pharmacy transaction database
• Managed process to update data each week at Web data-hosting site Perot Systems based in Dallas
• Co-inventor of patented application “System and method for analyzing de-identified health care data”

Lead Analyst, Epidemiology Resources Inc. (1995 –1998)

• Analyzed United Health Care claims database to address the safety of new leukotriene receptor antagonist
• Designed and created relational database of pooled multi-national clinical trial database to demonstrate the effectiveness of new asthma therapy
• Analyzed in-house health plan claims database to evaluate the cost-effectiveness of medications and assess the safety of medications based on medical event rates

* Member International Society Pharmocoepidemiology (ISPE)

Education

Doctoral student, Pharmacoepidemiology University of Rhode Island, Kingston, Rhode Island

MS Degree, Statistics University of Rhode Island, Kingston, Rhode Island (August 1996)

BS Degree, Mathematics Education and Applied Statistics (minor) Boston University, Boston, Massachusetts (May 1993)

New England Epidemiology Institute, summers 1996-98 Tufts University, Medford, MA

• Introduction to Epidemiology, Survival Analysis, Clinical Trials

Computer Software / Applications
SAS, Stata, Oracle, Foxpro, Sybase, StatView, Access, Excel, PowerPoint

Publications

Thomas A. Burke, Miriam C. Sturkenboom, Pamela A. Ohman-Strickland, Charles E. Wentworth, George G. Rhoads. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiology and Drug Safety. Published Online: 2 Jul 2007

Jara M, Lanes S, Wentworth C, May C, Kesten S. Comparative Safety of Long-Acting Inhaled Bronchodilators. Drug Safety, 2007; 30 (12): 1151-1160.

Arellano FM, Wentworth C, Arana A, Fernandez C, Paul C. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Journal of Investigative Dermatology, 2007; 127, 808-816.

Keston S, Jara M, Wentworth C, Lanes S. Pooled Clinical Trial Analysis of Tiotropium Safety. Chest, 2006; 130:1695-1703

Arellano FM, Yood M, Wentworth C, Oliveria S, Rivero E, Verma A, Rothman K. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAID) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiology and Drug Safety 2006; 15: 861-872

Burke TA, Sturkenboom MC, Lu S, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. Journal Hypertension 2006; 24:1193–1200.

Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug Switching Patterns Among Patients With Rheumatoid Arthritis and Osteoarthritis Using COX-2 Specific Inhibitors and Non Specific NSAIDs. Pharmacoepidemiology and Drug Safety 2004, 13(5):277-287

Rothman KJ, CE Wentworth. Mortality of cystic fibrosis patients receiving tobramycin solution for inhalation. Epidemiology 2003, 14(1):55-59

Osterhaus, J, C May, T Burke, CE Wentworth. Physician-reported management of edema and destabilized blood pressure in COX-2 specific inhibitor users with OA and treated hypertension. Clinical Therapeutics, 2002; volume 24, number 6 (969-989)

Johnson ES, SF Lanes, CE Wentworth, MH Satterfield, BL Abebe, LW Dicker. A metaregression analysis of the dose-response effect of aspirin on stroke. Archives of Internal Medicine, 1999; 159:1248-1253

Lanes SF, JE Garrett, CE Wentworth, JM Fitzgerald, JP Karpel. The effect of adding nebulized ipratropium bromide to salbutamol (albuterol) in the treatment of acute asthma: a pooled analysis of three trials. Chest, 1998; 114:365-372

Lanes SF, LL Lanza, CE Wentworth. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. American Journal of Respiratory and Critical Care Medicine, 1998; 158:857-861

Zhao SZ, Wentworth C, Burke TA, Makuch RW.Duration of Treatment with Celecoxib, Rofecoxib, and Non-Specific NSAIDs Among Managed Care Enrollees with Rheumatoid Arthritis and Osteoarthritis: A Measure of Comparative Drug Effectiveness. Value in Health, submitted.

Zhao SZ, Wentworth C, Makuch RW. Re-Initiation of NSAIDs and COX-2 Specific Inhibitors Following Treatment Discontinuation Among Arthritis Patients in a US Managed Care Organization. Journal of General Internal Medicine, submitted.

download pdf